Short Squeeze, page-150

First 150 Last

Share
Profile

Follow
jsonm

112 Posts.

143

11/03/22

11:14

Post #: 60134351
Share

Originally posted by stockrock: ↑

Some participants on this forum show no attempt to research Mesoblast and share unresearched and bias views on the company, obviously here for a free education. But schooling takes time and effort that IMO lazy students doesn't deserve.

If they had done their research, and simply listened to the most recent quarterly call he would be well aware that Mesoblast are at the cusp of significant milestones which could result in a strong re-rate.

1. COVID ARDs trial is waiting on the Ryoncil BLA, but Mesoblast are working with the NIH to get this set up.

2. Second CLBP Phase 3 trial is planning and working out how large the trial needs to be etc, with 'strategic partners' ...

3. Ryoncil BLA resubmission is just around the corner, with the timing of the FDA review likely to be driven by how quickly they can complete the Singapore Lonza manufacturing facility

4. CHF FDA approval pathway meeting with the FDA also just around the corner, providing clarity on next steps.

5. Colitus Investigator lead phase 2 interim results were so good, an early stop may be recommended and will go straight to a pivotal phase 3 trial.All this and more if he had just listened to the most recent Mesoblast quarterly call.

Some posters are not really good at research when they try and do it on a company they own, let alone ones they don't.

For example on a clinical stage biotech, I said that company was underfunded for their two phase 3 trials and needed a cap raise, but some poster said they were fully funded and no cap raise required... guess what $75m equity facility announced earlier this year.... I said the recruitment and read-out were going to be delayed, some poster said they may surprise and finish recruitment early... guess what 9 month delay announced last week, now mid-late 2024.There is an ignore function that I am using to avoid having to waste time educating people who makes no attempt to research Mesoblast.

Expand

I wonder who you could be referring to?

Why would anyone bother spending their time trashing a stock they don't hold? For some, their behaviour is absolutely pathological, down to a tee.

I refrained from bolding the very important first and last words in the sentence above, mostly to help certain other contributors avoid wasting their afternoon being triggered into an absolute downramping frenzy.

MSB Price at posting: $1.17 Sentiment: Buy Disclosure: Held
14 Upvote

4 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ACW

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

There are more pages in this discussion • 356 more messages in this thread...

First 150 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.52		Change 0.055(3.77%)		Mkt cap ! $1.729B

Open	High	Low	Value	Volume
$1.48	$1.54	$1.45	$6.072M	4.049M

Buyers (Bids)

No.	Vol.	Price($)
1	5951	$1.52

Sellers (Offers)

Price($)	Vol.	No.
$1.52	133644	5

View Market Depth

No.	Vol.	Price($)
1	5951	1.515
2	25946	1.510
3	69790	1.505
10	85830	1.500
5	49557	1.495

Price($)	Vol.	No.
1.520	133644	5
1.525	36900	5
1.530	108768	5
1.535	48010	6
1.540	113241	11

Last trade - 16.10pm 12/11/2024 (20 minute delay)

MSB (ASX) Chart

Short Squeeze, page-150

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Short Squeeze, page-150

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News